Adam D. Levy is Senior Vice President of Corporate Affairs and Investor Relations at Acrivon Therapeutics, Inc. Previously, he served as Senior Vice President of Investor Relations at Zentalis Pharmaceuticals, Inc. Prior to Zentalis, he was Senior Vice President of Investor Relations and Corporate Communications at Turning Point Therapeutics, where he was part of the team that delivered a $4.1B transaction when the company was acquired by Bristol Myers Squibb in 2022. Earlier in his career he held positions of increasing responsibility in Corporate Strategy and Corporate Development at Pfizer Inc., Novartis AG, Alexion Pharmaceuticals and Gilead Sciences, where he was Head of Corporate Strategy. Adam also served as an Engagement Manager at McKinsey and Company, focusing on supporting clients in the pharmaceutical industry. Adam received an MBA from the Kellogg School of Management at Northwestern University, a PhD in Molecular Biology from the University of Illinois at Chicago, and a BS in Genetics from the University of Illinois at Urbana-Champaign.
Dr. Shacham co-founded E44 Ventures in June 2022 and serves as Managing Director. Dr. Shacham co-founded Karyopharm in 2008 and served as their Chief Scientific Officer from October 2010 to May 2022. She was also President of Research and Development from December 2012 to May 2021. From 2010 to 2012, Dr. Shacham served as the Chief Scientific Officer and Head of Research and Development, and prior to that, as President and Chief Executive Officer. Dr. Shacham currently is a member of the Scientific Advisory Board of Karyopharm.
Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials.
Dr. Shacham holds a Bachelor of Science in Chemistry, a Doctor of Philosophy in Biophysical Chemistry, and a Master of Business of Administration from Tel Aviv University.
Kristina Masson, Ph.D., MBA, is Co-Founder and EVP, Business Operations at Acrivon Therapeutics, Inc. and President and CEO of the company´s research subsidiary Acrivon AB located in Medicon Village, Sweden. Here she has established all infrastructure, heads all operations, and runs the phospho- proteomic discovery hub and early drug programs for the company’s proprietary AP3 platform. In 2016, she founded and operated OncoSignature AB, a small biotech company focused on identifying predictive biomarkers for clinical-stage cancer therapeutics for U.S. companies. OncoSignature’s business was subsequently acquired by Acrivon AB. Prior to that, she was a Principal Scientist at Merrimack Pharmaceuticals, Cambridge, MA where she co-led, managed, and participated in cross-functional teams in both preclinical and clinical-stage therapeutic antibody programs, designing projects to identify predictive biomarkers, combination strategies and resistance mechanisms. Before joining Merrimack Pharmaceuticals, Kristina was a Post-Doctoral Fellow in the Golub lab at the Broad Institute of MIT and Harvard, developing assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer. Kristina received her M.Sc. and Ph.D. from Lund University, Sweden, and she received her Executive MBA from the Massachusetts Institute of Technology Sloan School of Management. Kristina is a member of the Board of Directors for Acrivon Therapeutics Inc. and Aqilion AB.
